---
title: "OKYO Pharma is scheduled to present data on their dry eye drug at an important conference."
publisher: "Share Talk"
author: "sharetalk"
published: "2023-05-03T06:29:57+00:00"
modified: "2023-05-03T06:29:57+00:00"
date: 2023-05-03
canonical: "https://www.share-talk.com/okyo-pharma-is-scheduled-to-present-data-on-their-dry-eye-drug-at-an-important-conference/"
category: "Healthcare"
categories: ["Healthcare", "Pharmaceutical"]
tags: ["biotechnology", "Bloomberg", "diseases", "Dr. Gary Jacob", "Dr. Napoleone", "dry eye", "inflammatory", "life sciences", "NASDAQ", "New York Medical College", "OKYO", "OKYO Pharma", "Share Talk", "Willy Simon"]
image: "https://i0.wp.com/www.share-talk.com/wp-content/uploads/2023/11/Stencil-Google-Chrome-2023-04-19-at-2.47.43-PM.jpeg?fit=1231%2C615&quality=89&ssl=1"
format: "news"
language: "en-GB"
---

# OKYO Pharma is scheduled to present data on their dry eye drug at an important conference.

**Published:** May 3, 2023
**Author:** sharetalk
**Categories:** Healthcare, Pharmaceutical
**Tags:** biotechnology, Bloomberg, diseases, Dr. Gary Jacob, Dr. Napoleone, dry eye, inflammatory, life sciences, NASDAQ, New York Medical College, OKYO, OKYO Pharma, Share Talk, Willy Simon
**Featured image:** ![](https://i0.wp.com/www.share-talk.com/wp-content/uploads/2023/11/Stencil-Google-Chrome-2023-04-19-at-2.47.43-PM.jpeg?fit=1231%2C615&quality=89&ssl=1)

---

**OKYO Pharma Ltd (LSE: OKYO, NASDAQ: OKYO),** a biopharmaceutical company focused on ophthalmology, is set to present two papers on their treatment for dry eye disease (DED), OK-101, at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, California, from May 5-8.

The presentations will be delivered by Dr. Pedram Hamrah, a renowned expert on DED and corneal neuropathic pain, who serves as the co-director of the Cornea Service and director of the Center for Translational Ocular Immunology at the New England Eye Center at Tufts Medical Center.

The papers will focus on pre-clinical and animal model data, demonstrating the effectiveness of OK-101 in treating DED and Neuropathic Corneal Pain (NCP). OK-101 is a potential breakthrough treatment aimed at addressing the significant unmet need in the multi-billion-dollar market for DED.

---

**Original URL:** https://www.share-talk.com/okyo-pharma-is-scheduled-to-present-data-on-their-dry-eye-drug-at-an-important-conference/
*Created by [WP Markdown Endpoint](https://wpmarkdownendpoint.com/)*